Oncology Times offentlig
[search 0]
Mer
Download the App!
show episodes
 
In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals. The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992. Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVi ...
  continue reading
 
Loading …
show series
 
Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the 2023 annual congress of the European Society for Medical Oncology (ESMO) held i…
  continue reading
 
Research presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics found that a combination of two drugs targeting the nRAS mutation had clinical activity in patients with checkpoint-inhibitor refractory melanoma and had potential for treating other solid tumors with mutated nRAS as their oncogenic d…
  continue reading
 
Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC int…
  continue reading
 
Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC internationa…
  continue reading
 
The Chloride Intracellular Channel 1 (CLIC1) protein appears to hold the key to understanding the anti-proliferative action of metformin, according to laboratory evidence discussed at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in October 2023, in Boston. At the conference, Michele M. Mazzanti, PhD,…
  continue reading
 
Dr. Takahashi talks with OncTimes Talk’s Peter Goodwin about the Phase 2 study he presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11 - 15, 2023. Dr. Takahashi reported an improvement in median overall survival among patients with relapsed small cell lung cancer who had the ATR inhibitor…
  continue reading
 
Acute myeloid leukemia (AML) is notoriously difficult to treat. Only 28 percent of patients survive beyond 5 years after diagnosis. Mitophagy, a process in which damaged mitochondria are eliminated to prevent the transmission of death signals, has been identified as a key mechanism that allows leukemia cells to resist the effects of the widely pres…
  continue reading
 
Some of the big randomized clinical trials could lead to unintentional bias because of an imbalance of assigned treatment discontinuations between experimental and control arms, according to ASCO poster author Faris Tamimi, MD, at the University Health Network Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre. OncTimesT…
  continue reading
 
Although T-DXd had already been licensed for use in all categories of HER2 positivity, including patients with so-called HER2-low tumors (defined as having immunohistochemical score of 1+ or 2+ with non-amplified in-situ hybridization), doubts have remained about the effectiveness of this antibody drug conjugate in the subset of such patients who a…
  continue reading
 
A mathematical study of real-world data from 27,855 women whose breast cancer was diagnosed between 2008 and 2020 has shown that a machine-learning artificial intelligence algorithm was able to predict mortality and could become a key weapon in the clinician’s armory when selecting therapies on the basis of predicted survival. Initial findings and …
  continue reading
 
Caution was expressed at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting about potential adverse effects from one form of breast cancer treatment de-escalation. A poster warns about risks from omitting axillary sentinel node surgery in older women. In this edition of OncTimesTalk correspondent Peter Goodwin hears about axillary…
  continue reading
 
A real-world study reported at the ESMO Breast Cancer 2023 Annual Congress identified a risk for inappropriate therapeutic decision-making resulting from an alarmingly high rate of false-negative tests coming from biopsy specimens looking for biological parameters such as PR and HER2. Study researchers at the University of Catania suggested tumor h…
  continue reading
 
Patients with breast cancer who complied fully with their adjuvant endocrine medication lived 15 percent longer than those who skipped doses, according to a huge real-world study coordinated from Tübingen University, in Baden-Württemberg, Germany, reported at the 2023 ASCO Annual Meeting. OncTimesTalk correspondent Peter Goodwin discusses the findi…
  continue reading
 
Being overweight or obese can reduce the benefit of extending adjuvant breast cancer hormone therapy in women younger than 60 years, according to research from the DATA trial discussed at the European Society for Medical Oncology (ESMO) Breast Cancer 2023 Congress. Senna W.M. Lammers, MD, from Maastricht University Medical Centre in The Netherlands…
  continue reading
 
Non-small cell lung cancer was one of the big topics at the 2023 ASCO Annual Meeting where Heather Wakelee, MD, FASCO, Professor of Medicine and Chief of the Division of Oncology at Stanford University in California, was overheard reminding a junior cancer doctor that the only adjuvant therapy for lung cancer had been chemotherapy just a couple of …
  continue reading
 
End-of-life care for patients with cancer could be significantly improved while simultaneously reducing cost according to the findings of a study from the University of Pennsylvania. Ravi Parikh, MD, MPH, talks with OncTimesTalk correspondent Peter Goodwin about his findings on the value of harnessing AI to help doctors have serious illness convers…
  continue reading
 
Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about his group’s findings from the international Phase III ADAURA clinical trial looking at adjuvant therapy with the anti EGFR-mutant drug osimertinib in patients with completely resected stage one B to thr…
  continue reading
 
Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about his group’s findings from the international Phase III ADAURA clinical trial looking at adjuvant therapy with the anti EGFR-mutant drug osimertinib in patients with completely resected stage one B to thr…
  continue reading
 
Progress in esophageal cancer is forging ahead at Columbia University in New York. Brian Henick, MD, is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract. As Associate Director of Experimental Therapeutics and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Henick…
  continue reading
 
Today we are introducing the new Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP. In her new role, Graff will help Oncology Times continue to provide essential clinical news and analysis for the cancer care community.Graff is Director of Breast Oncology at Lifespan Cancer Institute and Assistant Professor of Medicine at Brown Uni…
  continue reading
 
When cancer advances to an incurable stage, some patients may prioritize treatment that will extend their life as long as possible, and others may prefer a care plan that’s designed to minimize pain. Talking to patients about their prognosis and values can help clinicians develop care plans that are better aligned to each patient’s goals. However, …
  continue reading
 
Despite increased screening and HPV vaccines, cervical cancer remains the fourth-leading cause of cancer death among women worldwide. Screening guidelines are constantly scrutinized and reassessed. The most current U.S. Preventative Services Task Force (USPSTF) guidelines recommend screening for cervical cancer every 3 years with cervical cytology …
  continue reading
 
This episode is Research Review, a quarterly review of the research you may have missed. Today, we are covering the American Society of Hematology Annual Meeting highlights. First Up, results from the ECOG-ACRIN E1910 Randomized Phase III clinical trial showed that blinatumomab improved overall survival in newly diagnosed adult patients with b-line…
  continue reading
 
Sarcoma represents an incredibly rare group of cancers comprised of 50 histologic subtypes, with approximately 13,000 new diagnoses per year. Each histologic type exhibits a unique biologic behavior, and, as such, prognosis and optimal treatment strategies vary. Sarcoma can appear anywhere in the body, and local invasion of nearby organs may make s…
  continue reading
 
A study using chimeric antigen receptor (CAR)-T cells has proven to be safe for treating patients with relapsed or refractory acute myeloid leukemia (AML). The agent known as PRGN-3006 also brought remissions among patients who had chemotherapy for lymphodepletion prior to their CAR-T cell procedure (Abstract 4633). After the lead author of the new…
  continue reading
 
Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer deaths worldwide. The current gold standard for screening, the colonoscopy, reduces cancer deaths by 67 percent, according to a 2018 study from Kaiser Permanente. So, we know screening is effective. However, obstacles remain. Colonoscopies are invasive and c…
  continue reading
 
BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor—the investigational drug ipatasertib—in a Phase I study reported at the 2022 EORTC—NCI—AACR symposium on Molecular Targets and Cancer Therapeutics. Nearly a quarter of the patients treated with the AKT blocker had their tumors …
  continue reading
 
BARCELONA, Spain—Liquid biopsies are increasingly used to identify cancer progression and could also provide molecular evidence of higher risk for hematologic malignancies and solid tumors, according to findings from a study of circulating tumor DNA reported at the European Organization for Research and Treatment of Cancer—National Cancer Institute…
  continue reading
 
In oncology today, there is an urgent need to better understand the implications of racial bias and disparities on the health outcomes of patients. Although breast cancer mortality rates decreased by 43 percent from 1989 to 2020, Black women remain more likely to die from breast cancer compared with White women, according to the 2022 American Cance…
  continue reading
 
We talk to Naveen Pemmaraju, MD, about the results of the largest prospective BPDCN trial evaluating the CD123-targeted therapy tagraxofusp in adults with treatment-naive and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare and aggressive myeloid malignancy of the dendritic cell lineage which can affect othe…
  continue reading
 
Today on OncTimes Talk, we are getting to know a clinical researcher in 5 questions. We sat down with Sandeep Mittan, PhD, FAHA, who is a Clinical Scientist in the Division of Women’s Health and Medical Oncology at the Montefiore Medical Center and The University Hospital for Albert Einstein College of Medicine in New York. His work investigates me…
  continue reading
 
PARIS, France—One of the most prominent late-breaking abstracts reported at ESMO 2022 in Paris was about a rare cancer, desmoid tumor, for which no standard therapy had yet been recommended and for which there had been a clear unmet need. A team from Germany presented new findings from a randomized study using nirogacestat, a “NOTCH inhibitor”—gamm…
  continue reading
 
The availability of a blood test for circulating DNA that can be used widely in healthy individuals to check for molecular signs of multiple cancers led Deb Schrag, MD, MPH, formerly of the Dana-Farber Cancer Center in Boston and currently Chair of the Department of Medicine at Memorial Sloan-Kettering Cancer Center, New York, to research it's use …
  continue reading
 
Journalist Peter Goodwin gives OncTimes Talk a whirlwind review of the top 2022 breast cancer research as he reports live in person from the 2022 ESMO Berlin meeting. Featuring the following interviews with leading experts: 1. Patient-Reported Outcomes Support First-Line Pembrolizumab in TNBC: David Cescon, MD, PhD, Medical Oncologist and Clinician…
  continue reading
 
In this edition of OncTimes Talk we’re taking a look at: extending life in patients with metastatic hormone-sensitive prostate cancer by adding a third drug to standard two-drug regimens. In the randomized Phase III ARASENS trial—just published in the New England Journal of Medicine—the androgen receptor inhibitor, darolutamide, was compared with p…
  continue reading
 
CAMBRIDGE, UK—OncTimesTalk visits genetics pioneer Nitzan Rosenfeld PhD, group leader at the Cancer Research UK Cambridge Institute, University of Cambridge, to learn about giant steps forward for lung cancer management—reported in the Annals of Oncology—made with the sensitive assay for circulating tumor DNA (ctDNA) they developed (2022; https://d…
  continue reading
 
At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin interviewed Marla Lipsyc-Sharf, MD, Medical Oncology Fellow at Dana-Farber Cancer Institute/Mass General Brigham, who reported what she believes is the first data on ctDNA detection in late adjuvant, hormone receptor-positive breast cancer. The research showed ctDNA testing was …
  continue reading
 
At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin caught up with Julia C. Tchou, MD, PhD, FACS, from the University of Pennsylvania Health System, during her poster session. Her research examined the feasibility and acceptability of a weight loss group program via telehealth for breast cancer survivors.…
  continue reading
 
At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin caught up with Alexander I. Spira, MD, PhD, FACP after his presentation on KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation (Abstract 9002).…
  continue reading
 
Colleague Conversations offers insights into hematology/oncology from two different perspectives: a seasoned hematologist/oncologist and a clinician earlier in their career. Oncology Times reporter Catlin Nalley sat down with Lucy A. Godley, MD, PhD, and Gina Keiffer, MD, to discuss germline predisposition to hematologic malignancies. They delve in…
  continue reading
 
As Russian forces continue to bombard Ukraine, concerns are mounting about the most vulnerable citizens there, including the ill and those with cancer. Today on OncTimes Talk, we review the war in Ukraine and discuss how the war is impacting cancer patients and health systems in neighboring countries. Trying to process the refugee flow is very daun…
  continue reading
 
A bilateral prophylactic mastectomy for women at high risk of developing breast cancer can reduce their risk of developing the disease by up to 90 percent, according to the National Cancer Institute. An increasing number of women, including young women, are taking up this option. And while the data shows mastectomy is an effective method of reducin…
  continue reading
 
While the threat of climate change may conjure images of sea level rise, extreme weather patterns, and drought, the full picture of how climate change will impact oncology practice and care is still emerging. We do know that climate change will impact cancer risk, increase exposure to carcinogens, impede access to care, and ultimately effect surviv…
  continue reading
 
In early February, President Joe Biden announced that he is supercharging the Cancer Moonshot program to accelerate progress against cancer and save lives. The ambitious, jumpstarted Cancer Moonshot aims to reduce the U.S. death rate due to cancer by at least 50 percent over the next 25 years, and to improve the lives of all Americans living with a…
  continue reading
 
Today we revisit three studies presented at the ASH 2021 Annual Meeting. Primary Analysis of ZUMA-7 The 2021 American Society of Hematology Plenary Sessions in Atlanta, Georgia, heard data from a new study of CAR-T cell therapy in patients with diffuse large B-cell lymphoma: the Phase III randomized ZUMA-7 trial. This compared Axicabtagene Ciloleuc…
  continue reading
 
Today we are bringing you a round up of three stories from around the world. We will start at the 2021 World Cancer Leader’s Summit, then move onto a story on how radiotherapy can cut late gastrointestinal toxicity for cervical cancer patients, and finish with lessons on what COVID has taught us about cancer care. All interviews are brought to you …
  continue reading
 
At the 2021 Annual Meeting of the American Society of Hematology, researchers presented more data on additional risks faced by patients who have acute leukemia or myelodysplastic syndrome and have become infected with COVID-19. In a key study presented at ASH, Dr. Pinkal Desai from New York’s Weill Cornell Medical College has identified clinical pr…
  continue reading
 
In this episode, we bring you new research from the 2021 American Society of Hematology Annual Meeting about the cellular processes involving the mutated TP53 oncogene that can convert a patient’s—fairly benign—myeloproliferative neoplasm into a very threatening acute myeloid leukemia. These have been under investigation at Oxford University in the…
  continue reading
 
A new study provides support for high effectiveness of the Pfizer COVID vaccine against hospital admissions up until around 6 months after being fully vaccinated. The real-world, retrospective cohort study included data from 3.4 million Californian residents and was recently published in The Lancet. The importance of this Californian study is that …
  continue reading
 
A new study has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC). The paper, titled “Crizotinib in Patients With MET-Amplified NSCLC,” published in the Journal of Thoracic Oncology, introduces a third means of defining NSCLC subsets that can be targeted with a specific drug. In th…
  continue reading
 
Loading …

Hurtigreferanseguide

Copyright 2023 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett